(Yicai Global) July 7 -- Shanghai Fosun Pharmaceutical (Group) Co. [600196.SH] will spend CNY500 million (USD73.5 million) to set up a technology innovation incubator which will be open to global innovative technologies and projects via a wholly-owned subsidiary. It is aimed at pushing forward its innovation and globalization strategies, the company said in a statement yesterday.

The incubation platform will last for nine years. Professor Xu Tian, deputy head of the genetics department at Yale University, will act as the chairman of the incubator's academic committee to oversee platform operations and management.

The incubator will look for, identify and foster innovation initiatives across the world, focusing on medicine, regenerative medicine and artificial intelligence projects, the statement noted. In future, it will invest in selected projects as a quasi-asset management company.

Fosun Pharma appointed Professor Xu as chief science advisor last year, public information shows. He has been involved in several startup investment and incubation projects.